Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amphastar Has First US Glucagon Rival

FDA Approves First Generic Version Of Eli Lilly’s Glucagon Emergency Kit

Executive Summary

Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.

You may also be interested in...



Amphastar Delivers Strong Quarter With Epinephrine Gains

Amphastar delivers back-to-back strong quarters as the company continues to see a rise in sales of its key products including Primatene Mist (epinephrine), glucagon and other epinephrine products. The company continues to build its pipeline and diversify its portfolio.

Primatene Mist First-Quarter Sales Grow 43% As Amphastar Expands Distribution

Sales of Primatene Mist and other higher-margin products drive Amphastar's ifrst-quarter r5esults. The company continues to target a combined market worth around $10.5bn with seven generics in development.

Amphastar Sees Its Strongest Quarter So Far

Amphastar has delivered a strong quarter due to an increased in sales of higher-margin products. The company continues to target a combined market worth around $10.5bn with seven generics in development. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150547

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel